Molecular Oncology
Volume 2, Issue 2 , Pages 153-160 , August 2008

Innovations, challenges and future prospects of oncoproteomics

Received 20 April 2008 ,Revised 8 May 2008 ,Accepted 20 May 2008.

References 

  1. Carney WP, Leitzel K, Ali S, Neumann R, Lipton A. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. 2007;9:207
  2. Cho WC, Cheng CH. Oncoproteomics: current trends and future perspectives. Expert Rev. Proteomics. 2007;4:401–410
  3. Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J. Gen. Intern. Med. 2008;23(Suppl. 1):78–84
  4. D'Amico TA. Molecular biologic staging of lung cancer. Ann. Thorac. Surg. 2008;85:S737–S742
  5. Drev P, Grazio SF, Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 2008;16:179–184
  6. Ebert MP, Korc M, Malfertheiner P, Rocken C. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J. Proteome. Res. 2006;5:19–25
  7. Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JM, Schellens JH, et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 2006;12:1536–1544
  8. Espina V, Wulfkuhle J, Calvert VS, Liotta LA, Petricoin EF. Reverse phase protein microarrays for theranostics and patient-tailored therapy. Methods Mol. Biol. 2008;441:113–128
  9. Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute leukemia. In:  Daoud SS editors. Cancer Proteomics. Totowa, New Jersey: Humana Press; 2008;p. 161–187
  10. Habermann JK, Bader FG, Franke C, Zimmermann K, Gemoll T, Fritzsche B, et al. From the genome to the proteome-biomarkers in colorectal cancer. Langenbecks Arch. Surg. 2008;393:93–104
  11. Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann. N Y Acad. Sci. USA. 2007;1107:223–230
  12. Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, et al. Serum proteomic patterns for ovarian cancer monitoring. Int. J. Gynecol. Cancer. 2007;
  13. Hu S, Yen Y, Ann D, Wong DT. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery. Drug Discov. Today. 2007;12:911–916
  14. Hwang SI, Thumar J, Lundgren DH, Rezaul K, Mayya V, Wu L, et al. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene. 2007;26:65–76
  15. Jain KK. Recent advances in oncoproteomics. Curr. Opin. Mol. Ther. 2002;4:203–209
  16. Jain KK. Proteomics-based anticancer drug discovery. In:  LaRochelle WJ editors. The Oncogenomics Handbook. Totowa, New Jersey: The Humana Press; 2005;p. 123–134
  17. Jain KK. Recent advances in clinical oncoproteomics. J. BUON. 2007;12(Suppl. 1):S31–S38
  18. Jain KK. Cancer biomarkers: current issues and future directions. Curr. Opin. Mol. Ther. 2007;9:563–571
  19. Jain KK. Proteomics: Technologies, Markets and Companies. Basel, Switzerland: Jain PharmaBiotech Publications; 2008;pp. 1–570
  20. Jain KK. Recent advances in nanooncology. Technol. Cancer Res. Treat. 2008;7:1–13
  21. Jain KK. Oncoproteomics for personalized management of cancer. In:  Daoud SS editors. Cancer Proteomics. Totowa, New Jersey: Humana Press; 2008;p. 81–99
  22. Johnson CJ, Zhukovsky N, Cass AE, Nagy JM. Proteomics, nanotechnology and molecular diagnostics. Proteomics. 2008;8:715–730
  23. Kim HK, Park WS, Kang SH, Warda M, Kim N, Ko JH, et al. Mitochondrial alterations in human gastric carcinoma cell line. Am. J. Physiol. Cell Physiol. 2007;293:C761–C771
  24. Kopf E, Zharhary D. Antibody arrays – an emerging tool in cancer proteomics. Int. J. Biochem. Cell Biol. 2007;39:1305–1317
  25. Lin JF, Xu J, Tian HY, Ga X, Chen QX, Gu Q, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int. J. Cancer. 2007;121:2596–2605
  26. Liu C, Shea N, Rucker S, Harvey L, Russo P, Saul R, et al. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics. 2007;7:4045–4052
  27. Lopez-Pedrera C, Villalba JM, Siendones E, Siendones E, Barbarroja N, Gomez-Diaz C, et al. Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics. 2006;6(Suppl. 1):S293–S299
  28. Nettikadan S, Radke K, Johnson J, Xu J, Lynch M, Mosher C, et al. Detection and quantification of protein biomarkers from fewer than ten cells. Mol. Cell. Proteomics. 2006;5:895–901
  29. Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR. Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J. Clin. Oncol. 2007;25:5578–5583
  30. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006;354:2103–2111
  31. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 2008;
  32. Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, Neumann R, et al. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. Am. J. Clin. Pathol. 2007;128:630–637
  33. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin. Radiat. Oncol. 2008;18:89–97
  34. Zhang JT, Liu Y. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer. Treat. Rev. 2007;33:741–756
  35. Zhao L, Liu L, Wang S, Zhang YF, Yu L, Ding YQ. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J. Cancer Res. Clin. Oncol. 2007;133:771–782

PII: S1574-7891(08)00069-0

doi: 10.1016/j.molonc.2008.05.003

Molecular Oncology
Volume 2, Issue 2 , Pages 153-160 , August 2008

Article Tools

* Image Usage & Resolution